Who is sponsoring NCT00216398?

NCT00216398 is sponsored by Ipsen.

What condition does NCT00216398 study?

NCT00216398 studies Acromegaly.

What drugs are being tested in NCT00216398?

Interventions: Lanreotide (Autogel formulation).

What is the status of NCT00216398?

NCT00216398 is currently COMPLETED.

Last reviewed 2019-08-14 · How we verify

A Phase IV, Open-label, Single Group Study to Evaluate the Dosing, Efficacy and Safety of Lanreotide Autogel® in Patients With Acromegaly Previously Treated With Octreotide LAR

NCT00216398 Phase 4 COMPLETED

The purpose of this study is to assess the efficacy, safety and patient acceptability of Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.

Details

Lead sponsor	Ipsen
Phase	Phase 4
Status	COMPLETED
Enrolment	8
Start date	2004-06
Completion	2006-06-22

Conditions

Acromegaly

Interventions

Lanreotide (Autogel formulation)

Primary outcomes

The percentage of patients with GH control (<5.0 mU.L) and normalised IGF-1 at week 44 compared to the baseline (Week 0) visit.

Countries

Australia